company background image
SYRS logo

Syros Pharmaceuticals NasdaqGS:SYRS Stock Report

Last Price

US$0.20

Market Cap

US$5.4m

7D

-3.5%

1Y

-97.2%

Updated

22 Dec, 2024

Data

Company Financials +

Syros Pharmaceuticals, Inc.

NasdaqGS:SYRS Stock Report

Market Cap: US$5.4m

SYRS Stock Overview

A biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. More details

SYRS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Syros Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Syros Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.20
52 Week HighUS$8.17
52 Week LowUS$0.18
Beta1.29
1 Month Change-31.79%
3 Month Change-89.36%
1 Year Change-97.16%
3 Year Change-99.45%
5 Year Change-99.71%
Change since IPO-99.89%

Recent News & Updates

Recent updates

Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout

Jul 02

Syros Pharmaceuticals: Rising Despite Dilution, A Must Look

Jan 14

Syros Pharmaceuticals: A Major Vote Of Confidence From Insiders

Sep 20

Syros gets FDA orphan drug designation for pancreatic cancer treatment SY-5609

Sep 13

Syros Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Shareholder Returns

SYRSUS BiotechsUS Market
7D-3.5%-3.6%-2.4%
1Y-97.2%-2.6%23.4%

Return vs Industry: SYRS underperformed the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: SYRS underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is SYRS's price volatile compared to industry and market?
SYRS volatility
SYRS Average Weekly Movement32.2%
Biotechs Industry Average Movement10.8%
Market Average Movement6.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: SYRS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SYRS's weekly volatility has increased from 21% to 32% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201168Gerald Quirkwww.syros.com

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.

Syros Pharmaceuticals, Inc. Fundamentals Summary

How do Syros Pharmaceuticals's earnings and revenue compare to its market cap?
SYRS fundamental statistics
Market capUS$5.37m
Earnings (TTM)-US$97.81m
Revenue (TTM)US$386.00k

13.9x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SYRS income statement (TTM)
RevenueUS$386.00k
Cost of RevenueUS$88.64m
Gross Profit-US$88.25m
Other ExpensesUS$9.56m
Earnings-US$97.81m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-3.65
Gross Margin-22,862.95%
Net Profit Margin-25,340.67%
Debt/Equity Ratio-369.3%

How did SYRS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:01
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Syros Pharmaceuticals, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leah Rush CannBrookline Capital Markets
Andrew FeinH.C. Wainwright & Co.
Jason ButlerJMP Securities